Outcomes of Novel JAK Inhibition for Moderate to Severe Rheumatoid Arthritis - Rheumatology Advisor

Outcomes of Novel JAK Inhibition for Moderate to Severe Rheumatoid Arthritis  Rheumatology Advisor

The Janus kinase (JAK) inhibitor peficitinib, taken once daily, was found to be safe and effective for the treatment of patients with moderate to severe rheumatoid ...



Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network